Advertisement

Drugs

pp 1–4 | Cite as

Caplacizumab: First Global Approval

  • Sean Duggan
AdisInsight Report

Abstract

Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody® caplacizumab (Cablivi™) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Based on positive results in phase II and III trials in patients with aTTP, caplacizumab was recently approved in the EU for the treatment of adults experiencing an episode of aTTP, in conjunction with plasma exchange and immunosuppression. This article summarizes the milestones in the development of caplacizumab leading to this first approval.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sean Duggan is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    European Medicines Agency. Cablivi (caplacizumab): summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 7 Sept 2018.
  2. 2.
    Sanofi. Cablivi™ (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP) [media release]. http://www.news.sanofi.us/. Accessed 3 Sept 2018.
  3. 3.
    European Medicines Agency. Cablivi (caplacizumab): EU assessment report. 2018. http://www.ema.europa.eu/ema/. Accessed 13 Jun 2018.
  4. 4.
    Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836–46.CrossRefGoogle Scholar
  5. 5.
    Ablynx. Understanding nanobodies. 2018. http://www.ablynx.com/technology-innovation/understanding-nanobodies/. Accessed 14 Sept 2018.
  6. 6.
    Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012;120(17):3603–10.CrossRefGoogle Scholar
  7. 7.
    Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118(3):757–65.CrossRefGoogle Scholar
  8. 8.
    Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511–22.CrossRefGoogle Scholar
  9. 9.
    Scully M, Cataland SR, Peyvandi F, et al. Results of the randomized, double-blind, placebo-controlled, phase 3 HERCULES study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura [abstract no. LBA-1 plus presentation]. Blood. 2017;130:1.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations